SCM
AVTX icon

Silverarc Capital Management’s Avalo Therapeutics AVTX Stock Holding History

Silverarc Capital Management’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.25M Buy
+500,402
New +$7.91M 0.96% 34
2026
Q1 		– Sell
-524,436
Closed -$9.52M – 75
2025
Q4 		$9.52M Sell
524,436
-196,486
-27% -$3.32M 1.32% 25
2025
Q3 		$9.16M Buy
+720,922
New +$6.2M 1.24% 27

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Silverarc Capital Management's AVTX Position: Q2 2026 in Review

Silverarc Capital Management opened a new position in Avalo Therapeutics (AVTX) in Q2 2026: 500,402 shares worth $9.25M. The stake represents 0.96% of the portfolio and ranks #34 among its holdings. This is a return to the name: Silverarc Capital Management previously reported a position in AVTX as recently as Q4 2025.

Silverarc Capital Management first reported a position in AVTX in Q3 2025 and has held it in 3 quarters since. The position peaked at $9.52M in Q4 2025. 126 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.

  • Silverarc Capital Management held 500,402 shares of Avalo Therapeutics worth $9.25M as of Q2 2026.
  • Avalo Therapeutics was a new Silverarc Capital Management position in Q2 2026.
  • Avalo Therapeutics made up 0.96% of Silverarc Capital Management's portfolio in Q2 2026, its #34 holding.
  • Silverarc Capital Management first reported a position in Avalo Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Silverarc Capital Management's Avalo Therapeutics position peaked at $9.52M in Q4 2025.
  • 126 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.

Based on Silverarc Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.